Virtus LifeSci Biotech Clinical Trials ETF
16 hedge funds and large institutions have $1.27M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
less funds holding
Funds holding: →
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
52% less capital invested
Capital invested by funds: $2.67M → $1.27M (-$1.4M)
Holders
16
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$35.8K | |
| 2 | +$34.2K | |
| 3 | +$20.3K | |
| 4 |
Wells Fargo
San Francisco,
California
|
+$6.32K |
Top Sellers
| 1 | -$881K | |
| 2 | -$264K | |
| 3 | -$12.9K | |
| 4 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$5.95K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$5.89K |